SKIC2 and cancer: We found that the MelARV ISDmut vaccine induced significantly higher immune responses and showed improved anti-cancer efficacy compared to the MelARV ISDwt vaccine [7], supporting the “ISD hypothesis” and indicating that a similar approach could be pursued for a vaccine targeting HERV-W in human cancers.